z-logo
Premium
A pyrazolylamine‐phosphonate monoester chelator for the fac ‐[M(CO) 3 ] + core (M = Re, 99m Tc): synthesis, coordination properties and biological assessment
Author(s) -
Palma Elisa,
Oliveira Bruno L.,
Figueira Flávio,
Correia João D. G.,
Raposinho Paula D.,
Santos Isabel
Publication year - 2007
Publication title -
journal of labelled compounds and radiopharmaceuticals
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.432
H-Index - 47
eISSN - 1099-1344
pISSN - 0362-4803
DOI - 10.1002/jlcr.1415
Subject(s) - chemistry , phosphonate , biodistribution , chelation , ligand (biochemistry) , amine gas treating , stereochemistry , organic chemistry , in vitro , biochemistry , receptor
Aiming to develop new strategies for the labeling of hydroxyl‐containing biomolecules with the organometallic core fac ‐[ 99m Tc(CO) 3 ] + , we have prepared a new model bifunctional chelator, L4 (ethyl hydrogen (2‐{[2‐(3,5‐dimethyl‐1 H ‐pyrazol‐1‐yl)ethyl]amino}ethyl)phosphonate), combining a pyrazolyl‐amine chelating group and a monophosphonate ethyl ester function (–P(O)OHOEt). The phosphonate group allows metal stabilization, and, simultaneously, can be considered as a potential attachment site for a biomolecule. Reaction of L4 with the precursor [ 99m Tc(H 2 O) 3 (CO) 3 ] + gave the model radiocomplex [ 99m Tc(CO) 3 (k 3 ‐L4)] ( 6a ). This radiocomplex was identified by comparing its chromatographic profile with that of the corresponding Re analog ( 6 ) under the same conditions, also prepared and fully characterized by the usual analytical techniques. Radiocomplex 6a is moderately lipophilic (log P o/w = 1.07), presenting high stability in vitro without any measurable decomposition or ligand exchange, even in the presence of strong competing chelators such as histidine and cysteine (37°C, 24 h). Biodistribution studies of the complex in CD‐1 mice indicated a rapid blood clearance, and a rapid clearance from main organs, occurring primarily through the hepatobiliary pathway. Complex 6a presents also a high robustness in vivo , demonstrated by its resistance to metabolic degradation in blood, and intact excretion into the urine, after RP‐HPLC analysis of blood and urine samples. Copyright © 2007 John Wiley & Sons, Ltd.

This content is not available in your region!

Continue researching here.

Having issues? You can contact us here
Accelerating Research

Address

John Eccles House
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom